

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2023 July 15; 15(7): 1105-1316



## Contents

Monthly Volume 15 Number 7 July 15, 2023

## REVIEW

- 1105** Role of ferroptosis in esophageal cancer and corresponding immunotherapy  
*Fan X, Fan YT, Zeng H, Dong XQ, Lu M, Zhang ZY*
- 1119** Core fucosylation and its roles in gastrointestinal glycoimmunology  
*Zhang NZ, Zhao LF, Zhang Q, Fang H, Song WL, Li WZ, Ge YS, Gao P*
- 1135** Interaction mechanisms between autophagy and ferroptosis: Potential role in colorectal cancer  
*Zeng XY, Qiu XZ, Wu JN, Liang SM, Huang JA, Liu SQ*
- 1149** Application of G-quadruplex targets in gastrointestinal cancers: Advancements, challenges and prospects  
*Han ZQ, Wen LN*

## MINIREVIEWS

- 1174** Clinical value of serum pepsinogen in the diagnosis and treatment of gastric diseases  
*Qin Y, Geng JX, Huang B*

## ORIGINAL ARTICLE

## Basic Study

- 1182** ENTPD1-AS1-miR-144-3p-mediated high expression of COL5A2 correlates with poor prognosis and macrophage infiltration in gastric cancer  
*Yuan HM, Pu XF, Wu H, Wu C*
- 1200** Clinical significance and potential application of cuproptosis-related genes in gastric cancer  
*Yan JN, Guo LH, Zhu DP, Ye GL, Shao YF, Zhou HX*

## Clinical and Translational Research

- 1215** Integrated analysis of single-cell and bulk RNA-seq establishes a novel signature for prediction in gastric cancer  
*Wen F, Guan X, Qu HX, Jiang XJ*

## Case Control Study

- 1227** Proteomics-based identification of proteins in tumor-derived exosomes as candidate biomarkers for colorectal cancer  
*Zhou GYJ, Zhao DY, Yin TF, Wang QQ, Zhou YC, Yao SK*

## Retrospective Cohort Study

- 1241** Development and validation of a postoperative pulmonary infection prediction model for patients with primary hepatic carcinoma  
*Lu C, Xing ZX, Xia XG, Long ZD, Chen B, Zhou P, Wang R*

**Retrospective Study**

- 1253** Clinical association between coagulation indicators and bone metastasis in patients with gastric cancer  
*Wang X, Wang JY, Chen M, Ren J, Zhang X*
- 1262** Efficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers  
*Zhang TW, Zhang P, Nie D, Che XY, Fu TT, Zhang Y*
- 1271** Development and validation of an online calculator to predict the pathological nature of colorectal tumors  
*Wang YD, Wu J, Huang BY, Guo CM, Wang CH, Su H, Liu H, Wang MM, Wang J, Li L, Ding PP, Meng MM*
- 1283** Efficacy of continuous gastric artery infusion chemotherapy in relieving digestive obstruction in advanced gastric cancer  
*Tang R, Chen GF, Jin K, Zhang GQ, Wu JJ, Han SG, Li B, Chao M*

**EVIDENCE-BASED MEDICINE**

- 1295** Comprehensive bioinformatic analysis of mind bomb 1 gene in stomach adenocarcinoma  
*Wang D, Wang QH, Luo T, Jia W, Wang J*

**CASE REPORT**

- 1311** Treatment of *Candida albicans* liver abscess complicated with COVID-19 after liver metastasis ablation: A case report  
*Hu W, Lin X, Qian M, Du TM, Lan X*

## Contents

*World Journal of Gastrointestinal Oncology*  
Monthly Volume 15 Number 7 July 15, 2023

### ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Zhi-Fei Cao, MD, PhD, Assistant Professor, Research Assistant Professor, Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu Province, China. [hunancao@163.com](mailto:hunancao@163.com)

### AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

### INDEXING/ABSTRACTING

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGO as 3.0; IF without journal self cites: 2.9; 5-year IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2022 is 4.1 and Scopus CiteScore rank 2022: Gastroenterology is 71/149; Oncology is 197/366.

### RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Xiang-Di Zhang; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

#### NAME OF JOURNAL

*World Journal of Gastrointestinal Oncology*

#### ISSN

ISSN 1948-5204 (online)

#### LAUNCH DATE

February 15, 2009

#### FREQUENCY

Monthly

#### EDITORS-IN-CHIEF

Monjur Ahmed, Florin Burada

#### EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

#### PUBLICATION DATE

July 15, 2023

#### COPYRIGHT

© 2023 Baishideng Publishing Group Inc

#### INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

#### GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

#### GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

#### PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

#### PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

#### ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

#### STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

#### ONLINE SUBMISSION

<https://www.f6publishing.com>

© 2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com) <https://www.wjgnet.com>



Retrospective Study

## Efficacy of continuous gastric artery infusion chemotherapy in relieving digestive obstruction in advanced gastric cancer

Rui Tang, Guo-Feng Chen, Kai Jin, Guang-Qiang Zhang, Jian-Jun Wu, Shu-Gao Han, Bin Li, Ming Chao

**Specialty type:** Oncology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Augustin G, Croatia;  
Kawabata H, Japan

**Received:** March 27, 2023

**Peer-review started:** March 27, 2023

**First decision:** May 4, 2023

**Revised:** May 17, 2023

**Accepted:** June 8, 2023

**Article in press:** June 8, 2023

**Published online:** July 15, 2023



Rui Tang, Kai Jin, Guang-Qiang Zhang, Jian-Jun Wu, Shu-Gao Han, Bin Li, Ming Chao, Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China

Guo-Feng Chen, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China

**Corresponding author:** Ming Chao, MD, Professor, Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310000, Zhejiang Province, China. [chaoming@zju.edu.cn](mailto:chaoming@zju.edu.cn)

### Abstract

#### BACKGROUND

Obstruction or fullness after feeding is common in gastric cancer (GC) patients, affecting their nutritional status and quality of life. Patients with digestive obstruction are generally in a more advanced stage. Existing methods, including palliative gastrectomy, gastrojejunostomy, endoluminal stent, jejunal nutrition tube and intravenous chemotherapy, have limitations in treating these symptoms.

#### AIM

To analyze the efficacy of continuous gastric artery infusion chemotherapy (cGAIC) in relieving digestive obstruction in patients with advanced GC.

#### METHODS

This study was a retrospective study. Twenty-nine patients with digestive obstruction of advanced GC who underwent at least one cycle of treatment were reviewed at The Second Affiliated Hospital of Zhejiang University School of Medicine. The oxaliplatin-based intra-arterial infusion regimen was applied in all patients. Mild systemic chemotherapy was used in combination with local treatment. The clinical response was evaluated by contrast-enhanced computed tomography using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Digestive tract symptoms and toxic effects were analyzed regularly. A comparison of the Karnofsky Performance Status (KPS) score and Stooler's Dysphagia Score before and after therapy was made. Univariate survival analysis and multivariate survival analysis were also performed to explore the key factors affecting patient survival.

#### RESULTS

All patients finished cGAIC successfully without microcatheter displacement, as confirmed by arteriography. The median follow-up time was 24 mo (95% CI: 20.24-27.76 mo). The overall response rate was 89.7% after cGAIC according to the RECIST criteria. The postoperative Stooler's Dysphagia Score was significantly improved. Twenty-two (75.9%) of the 29 patients experienced relief of digestive obstruction after the first two cycles, and 13 (44.8%) initially unresectable patients were then considered radically resectable. The median overall survival time (mOS) was 16 mo (95% CI: 9.32-22.68 mo). Patients who received radical surgery had a significantly longer mOS than other patients ( $P$  value < 0.001). Multivariate Cox regression analysis indicated that radical resection after cGAIC, intravenous chemotherapy after cGAIC, and immunotherapy after cGAIC were independent predictors of mOS. None of the patients stopped treatment because of adverse events.

## CONCLUSION

cGAIC was effective and safe in relieving digestive obstruction in advanced GC, and it could improve surgical conversion possibility and survival time.

**Key Words:** Intra-arterial infusion chemotherapy; Intravenous chemotherapy; Interventional radiology; Digestive obstruction; Advanced gastric cancer; Response evaluation criteria in solid tumors

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** This was a retrospective study to evaluate the effectiveness of continuous gastric artery infusion chemotherapy (cGAIC) in relieving digestive obstruction in advanced gastric cancer patients. The overall response rate was 89.7% after cGAIC. A total of 75.9% of patients experienced relief of digestive obstruction after the first two cycles, and 44.8% of initially unresectable patients were then considered radically resectable. The median overall survival was 16 mo. C-arm computed tomography angiography helped to precisely confirm the tumor-feeding artery. Our new treatment can not only help relieve patients with digestive obstruction but also provide a good prognosis in treating tumors.

**Citation:** Tang R, Chen GF, Jin K, Zhang GQ, Wu JJ, Han SG, Li B, Chao M. Efficacy of continuous gastric artery infusion chemotherapy in relieving digestive obstruction in advanced gastric cancer. *World J Gastrointest Oncol* 2023; 15(7): 1283-1294

**URL:** <https://www.wjgnet.com/1948-5204/full/v15/i7/1283.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v15.i7.1283>

## INTRODUCTION

Gastric cancer (GC) is the fifth most frequently diagnosed cancer and the third most common cause of cancer-related death worldwide[1]. Due to the insidious onset, 80%-90% of patients in China are initially diagnosed at an advanced stage without the possibility of radical surgery. The poor prognosis objective response rate (ORR) varies from 29% to 47%, and the median overall survival time (mOS) ranges from 7.2 to 14.6 mo[2]. Obstruction or fullness after feeding is common, occurring in 31.6% of GC patients, affecting their nutritional status and quality of life[3]. Chen *et al*[3] found that GC with digestive obstruction was more aggressive and metastatic, indicating that patients with digestive obstruction are generally in a more advanced stage. Therefore, relieving these symptoms and resuming oral feeding as much as possible have become the main therapeutic aim of patients with advanced GC accompanied by digestive obstruction.

National Comprehensive Cancer Network (NCCN) gastric cancer guidelines and Japanese gastric cancer treatment guidelines recommend that intravenous chemotherapy should be considered first in patients with advanced GC, while palliative gastrectomy, gastrojejunostomy, endoluminal stent, jejunal nutrition tube and other treatments are available to relieve digestive obstruction[1,4]. However, surgical operations are not suitable for patients in poor general condition. Despite the efficacy of endoluminal stents and jejunal nutritional tubes, the incidence of postoperative complications is high, such as stent displacement (16%-36%) and restenosis (17%-36%)[5]. In addition, no significant oral feeding improvement was obtained in more than 50% of patients following radiotherapy[6]. Previous studies found the potential role of chemotherapy in relieving digestive obstruction[7,8]. Neoadjuvant chemotherapy can also decrease the stage (40.7%-73.3%) in patients with locally advanced GC[9-12]. However, systemic intravenous chemotherapy is hardly tolerated by patients in poor condition.

In recent years, the usage of intra-arterial chemotherapy has gradually increased as an alternative to intravenous chemotherapy, such as hepatic artery infusion chemotherapy[13]. Research has shown mild adverse effects and significant efficacy, with better tolerance than intravenous chemotherapy[9,11,14]. It has also achieved encouraging results (ORR: 59.5%-85.4%, mOS: 9-30 mo) in patients with advanced GC[15-17]. However, no studies on relieving digestive obstruction have been reported. Thus, this study retrospectively analyzed patients with advanced GC-induced cardia or pyloric obstruction treated by constant gastric artery infusion chemotherapy (cGAIC). This study aimed to assess the safety and efficacy of this new method in relieving digestive obstruction.




Figure 1 Patients enrollment processes flow diagram.

## MATERIALS AND METHODS

### Patients

From September 2017 to April 2022, a total of 61 patients with advanced GC were analyzed retrospectively. Among them, 25 patients without obvious digestive obstruction symptoms were excluded. Of the remaining 36 patients, 6 were excluded because of inadequate follow-up, of which 2 lacked a pathological diagnosis, 3 did not undergo radiological review, and 1 lost contact. In addition, 1 case was removed due to having to relieve the obstruction through gastrojejunostomy before intervention. Finally, twenty-nine advanced GC-induced digestive obstruction patients (20 male, 9 female, aged 45-82 years, mean  $64.28 \pm 8.49$  years) who were unable to undergo radical surgery or failed to respond to radiotherapy or intravenous chemotherapy within a sufficient observation time were eligible for this study. All patients passed the examination and approval of the Ethics Committee of The Second Affiliated Hospital of Zhejiang University School of Medicine (Approval No. I2020001737) and gave signed informed consent. All patients were diagnosed by endoscopy and confirmed by pathology. In this study, advanced GC included locally advanced unresectable GC or metastatic GC. Clinical tumor-node-metastasis (cTNM) stage distribution was confirmed by contrast-enhanced computed tomography (CT) according to the 8th edition American Joint Committee and Union International Center Cancer (AJCC/UICC)[18]. Details of the patient selection processes are shown in Figure 1.

### Inclusion criteria

Patients with advanced GC who met the following criteria were included: (1) Experienced obstruction or fullness after feeding in stage III or IV according to Stooler's Dysphagia Score; (2) had a Karnofsky Performance Status (KPS) score > 50; (3) had initially unresectable advanced GC according to a gastrointestinal surgeon; (4) had no indication for further radical surgery; and (5) had no contraindications for interventional therapy and chemotherapy.

### Exclusion criteria

Patients with inadequate follow-up, acute infection, severe liver and kidney dysfunction or blood coagulation disturbance and pregnant and breastfeeding women were excluded.

### Treatment regimens

The framework of the chemotherapy regimen is based on the SOX (S-1 and oxaliplatin) intravenous chemotherapy regimen according to The NCCN Clinical Practice Guidelines for Gastric Cancer. In this study, the treatment regimen consisted of intra-arterial infusion of oxaliplatin 100 mg in 5 h and oral S-1 40 mg/m<sup>2</sup> twice a day for 14 d[14,19,20]. 5-Fluorouracil 2600 mg/m<sup>2</sup> d1 was administered intravenously if the patients could not take S-1 orally. Symptomatic antiemetic treatment and rehydration were used postcGAIC. Laboratory examination and abdominal contrast-enhanced CT were performed after 2 wk[21]. The KPS score and Stooler's Dysphagia Score were obtained from telephone follow-up after leaving the hospital. This cycle was repeated once every 3 wk.

### Interventional approaches

Interventional treatments were performed by two interventional radiologists with more than 10 years of experience. After femoral artery puncture using Seldinger's approach, a microcatheter was used for angiography of possible tumor-feeding arteries, including the left gastric artery, right gastric artery, right gastroepiploic artery or anomalous origin of the gastric



**Table 1** Infusion area in interventional approaches

Infusion area	Gastroesophageal junction obstruction, <i>n</i>	Pyloric obstruction, <i>n</i>	Anastomosis obstruction, <i>n</i>
Left gastric artery	13	5	1
Right gastric artery	1	3	0
Right gastroepiploic artery	0	13	2
Left gastric artery and right gastroepiploic artery	5	0	0
Right gastric artery and right gastroepiploic artery	0	23	0
Left gastric artery and right gastric artery	1	1	0
Others	7 <sup>1</sup>	6 <sup>2</sup>	1 <sup>2</sup>

<sup>1</sup>Including left gastroepiploic artery, left Inferior phrenic artery, superior mesenteric artery branch.

<sup>2</sup>Including common hepatic artery, coeliac trunk artery.

artery. C-arm computed tomographic angiography (CACTA) during interventional operation was then used to confirm the tumor-feeding artery according to preoperative abdominal contrast-enhanced CT. When selection of the tumor-feeding artery was complete, a vascular sheath and catheters were fixed to the skin, and a mixture of oxaliplatin 100 mg and 250 mL 5% glucose solution was infused by a chemotherapy pump over 5 h (50 mL/h). If 2 tumor-feeding arteries existed, 2 microcatheters were placed at the same time through the bilateral femoral artery, and oxaliplatin 50 mg was equally infused into these arteries (Table 1). After infusion, angiography was performed again to confirm the location of the microcatheter.

The cycles of cGAIC depended on the following stop criteria: (1) The patient could not tolerate continuing chemotherapy; (2) the patient was evaluated as having progressive disease after 2 cycles of cGAICs; (3) the patient was evaluated as having a complete response after cGAIC; (4) the initially unresectable patient was considered resectable and received radical distal subtotal gastrectomy; and (5) the digestive obstruction was relieved, but the patient was still not resectable, and palliative treatment continued.

### Evaluation criteria

Radiology responses were assessed by two experienced radiologists independent from the clinical teams. Response Evaluation Criteria In Solid Tumors (RECIST) criteria were used to evaluate tumor response[22]. Complete disappearance of the tumor was considered to be complete response (CR); at least 30% decrease in tumor size was defined as partial response (PR); at least 20% increase in tumor size was defined as progressive disease (PD); and neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease was considered stable disease (SD). KPS scores from 0 to 100 were used to reflect general physical condition. Digestive obstruction was divided into five levels according to Stooler's Dysphagia Score: 0, normal swallowing; I, semidry food; II, soft food; III, fluid; and IV, completely unable to feed orally. Adverse events in this study included postoperative nausea and vomiting, abdominal pain, gastrointestinal hemorrhage, bone marrow hypocellular, paresthesia and increased levels of liver enzyme. Adverse events were assessed according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

### Statistical analysis

Comparison of the KPS score and Stooler's Dysphagia Score before and after therapy was performed using the Wilcoxon signed-rank test. Comparisons of parameter variables were performed using the paired samples test. Univariate survival analysis was performed using the Kaplan-Meier method, and multivariate survival analysis was performed using a Cox regression model. Factors with  $P < 0.05$  in univariate survival analysis were included in the Cox regression model. Statistical analysis was performed using SPSS version 19.0 (SPSS Inc., Chicago, IL, United States). Two-tailed  $P < 0.05$  was considered significant.

## RESULTS

Among all patients, the median follow-up time was 24 mo (95%CI: 20.24-27.76 mo). All patients were given a total of 82 cGAIC cycles, and the median number of cycles was 3 (1-6). Of these patients, 6 had gastroesophageal junction cancer (Siewert III), 2 had recurrent tumors on anastomosis, and the remaining 21 had GC in the pylorus. During the follow-up, 13 (44.8%) initially unresectable patients were still unresectable and received radical distal subtotal gastrectomy (Billroth II) combined with D2 lymph node dissection, including 1, 3, 4 sb, 5, 6, 7, 8a, 9, 11p, 12a, and 14 V if necessary. Further postoperative intravenous chemotherapy was applied in these 12 patients, excluding 1 patient with poor health status



after gastrectomy. Metastatic disease is mainly treated by systemic therapy, including intravenous chemotherapy or immunotherapy. Only in a few patients were implantation metastases dissected for biopsy; details are shown in the [Supplementary Table 1](#). Other patients continued to carry immune checkpoint inhibitor treatment only (2 patients), intravenous chemotherapy only (5 patients), immune checkpoint inhibitors combined with intravenous chemotherapy (2 patients), best supportive care (5 patients), or gave up further treatments for poor health status and death (2 patients). All patients finished cGAIC successfully without microcatheter displacement, as confirmed by arteriography.

None of the twenty-nine patients showed PD after the treatment evaluated by the RECIST criteria, while the overall response (OR) was 89.7%, and the objective response rate (ORR) was 86.2% after the first cGAIC, 88.9% after the second cGAIC, 84.2% after the third cGAIC, and 100% after the 4-6th cycles of cGAIC by the RECIST criteria ([Table 2](#)).

Significant differences were found in Stooler's Dysphagia Score before and after treatment (before:  $3.24 \pm 0.43$ , after:  $2.13 \pm 0.78$ ,  $P$  value  $< 0.001$ ). Nineteen patients experienced relief of digestive obstruction after the first cGAIC, 3 patients experienced relief of digestive obstruction after the second cGAIC, and 7 patients did not recover from digestive obstruction ([Table 3](#)). Two temporarily recovered patients developed obstruction again after the third cGAIC. The KPS (before:  $61.79 \pm 6.58$ , after:  $71.43 \pm 5.15$ ,  $P$  value  $< 0.001$ ) score increased after cGAIC.

The median overall survival time (mOS) was 16 mo (95%CI: 9.32-22.68 mo, [Figure 2A](#)). Subgroup analysis showed that patients who were relieved of obstruction had a slightly longer mOS than patients who were not (21 *vs* 7 mo,  $P = 0.078$ , [Figure 2B](#)). Patients who received radical surgery had a significantly longer mOS than other patients (unobtained for low follow-up time *vs* 10 mo,  $P$  value  $< 0.001$ , [Figure 2C](#)).

In the exploratory univariate analysis shown in [Table 4](#), there were significant associations between mOS and intravenous chemotherapy history, pathology, radical resection after cGAIC, intravenous chemotherapy after cGAIC, and immunotherapy after cGAIC (all  $P < 0.05$ ). In addition, multivariate Cox regression analysis indicated that radical resection after cGAIC, intravenous chemotherapy after cGAIC, and immunotherapy after cGAIC were independent predictors of mOS (all  $P < 0.05$ ). We also observed that relieving digestive obstruction was not significantly associated with mOS.

Obvious imaging changes were found in the review of abdominal contrast-enhanced CT compared with preoperative CT. Pyloric obstruction or gastroesophageal junction obstruction ([Figure 3A and B](#)) manifested as thickening of the gastric wall, blurring of the boundary, and narrowing or disappearance of the digestive tract. After the first cGAIC, the abnormally thick gastric wall became thin, the blurred boundary became clear, and the blocked digestive tract opened again ([Figure 3E and F](#)).

Adverse events after intra-arterial infusion chemotherapy show a similar representation but a lower degree compared with those in intravenous chemotherapy in past studies ([Table 5](#)). No serious complications, such as gastrointestinal perforation or hemorrhage, were found. All the chemotherapy-related adverse events during cGAIC were not greater than grade 2 according to CTCAE and disappeared rapidly in the following week. None of the patients stopped treatment because of severe adverse events.

## DISCUSSION

The efficacy and safety of intra-arterial infusion chemotherapy have been confirmed in the treatment of advanced GC by inhibiting cell proliferation and inducing apoptosis. Zhang *et al* [16] found that preoperative intra-arterial infusion chemotherapy was an independent factor for the long-term survival of patients with advanced GC. Zhang *et al* [17] found an mOS of 25 mo in advanced GC while using intra-arterial chemotherapy, which was better than the mOS of 9 mo when using single intravenous chemotherapy. In addition, studies have shown that weight loss or malnutrition during neoadjuvant chemotherapy are independent risk factors for the effect, which indicates the importance of relieving digestive obstruction [23]. However, relief of digestive obstruction is not mentioned in the previous literature, and the intra-arterial infusion chemotherapy regimen lacks standardized guidance. Therefore, this study aimed to explore the efficacy and safety of cGAIC in advanced GC patients with digestive obstruction.

After the first treatment, patients immediately achieved an 86.2% ORR, which is better than the ORR (29%-47%) in a previous study in advanced GC with digestive obstruction, and no patient exhibited disease progression in the following treatment [1]. In addition, the clinical symptoms of digestive obstruction were relieved quickly in the follow-up visits, indicated by most patients beginning to resume oral feeding, which was an encouraging result for advanced GC patients with poor oral feeding. The KPS score was also improved compared with that before treatment, with better quality of life. No patients stopped treatment because of severe adverse events, which represented good clinical compliance. There may be some key factors in our regimen that are important for the satisfactory clinical effect.

The first key factor is to infuse the tumor-feeding artery accurately using CACTA. In recent studies, the infusion area of intra-arterial chemotherapy was chosen empirically according to the tumor location instead of being guided by CACTA. This may lead to choosing the wrong infusion area, resulting in weak responses compared with intravenous chemotherapy and unnecessary adverse reactions such as ischemia and ulcers. Tao *et al* [24] and Ji *et al* [25] found that the clear tumor blood supply in GC is an independent risk factor for OS. Wang *et al* [26] also confirmed that distinct tumor staining intraoperatively could affect prognosis. Therefore, it is important to place the microcatheter in the right location. In this study, the combination of intraoperative CACTA with preoperative contrast-enhanced CT may help with accurate treatment ([Figure 3C and D](#)) and avoid injuring important organs. For example, we should place the microcatheter in the right gastropiploic artery when possible and avoid the pancreaticoduodenal artery and duodenal artery to prevent pancreatitis or duodenal ulcers. One case in this study failed to relieve digestive obstruction because of an error in evaluating the dual feeding artery. In the following treatment, both arteries were infused, and the obstruction was

**Table 2 Tumor radiologic response evaluated by Response Evaluation Criteria In Solid Tumors criteria**

	After the first cGAIC, n (%)	After the second cGAIC, n (%)	After the third cGAIC, n (%)	After the fourth cGAIC, n (%)	After the fifth cGAIC, n (%)	After the sixth cGAIC, n (%)
CR	0 (0)	1 (3.7)	4 (21.1)	0 (0)	0 (0)	0 (0)
PR	25 (86.2)	23 (85.2)	12 (63.2)	3 (100)	2 (100)	2 (100)
SD	4 (13.8)	3 (11.1)	3 (15.8)	0 (0)	0 (0)	0 (0)
PD	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Total	29	27	19	3	2	2

Date in parentheses are percentages. Total = number of patients finished the treatments. cGAIC: Continuous gastric artery infusion chemotherapy; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

**Table 3 Comparison of Stooler's Dysphagia Score**

	Before cGAIC, n	After cGAIC, n	P value
Stooler's Dysphagia Score			< 0.001
I	0	6	
II	0	14	
III	22	8	
IV	7	1	

Stooler's Dysphagia Score reflected the degree of digestive obstruction. I: Semi dry food; II: Soft food; III: Fluid; IV: Completely unable to feed orally; cGAIC: Continuous gastric artery infusion chemotherapy.

relieved.

Another reason contributing to the better treatment may be the infusion time. Compared to 2-6 h continuous infusion in standard intravenous chemotherapy regimens, we infused concentration-dependent drugs through the arterial pathway persistently by a chemotherapy pump in 5 h. In previous studies, drugs were injected into the target area within a few minutes to produce a higher local drug concentration, which is simple and convenient but is not conducive to maintaining blood concentration for a long period[15]. In the postoperative biopsy in Zhang *et al's* study, they found gastric mucosal necrosis and scarring in the area of intra-arterial infusion treatment[17]. A high concentration of drugs was confirmed in blood samples from the portal vein by the left gastric intra-arterial route, which was 4-40-fold of the group by intravenous administration[26]. This higher local drug concentration may lead to arterial inflammation, promoting tumor cell ischemia and necrosis. A constant higher drug concentration may induce tumor cell apoptosis more effectively, which may be the pathophysiological mechanism of this treatment.

Therefore, in our accurate and constant intra-arterial infusion chemotherapy, the mOS was 16 mo, which was greater than expected. Because cGAIC has a high efficiency in shrinking the local lesion in the cardia or pylorus, the obstruction symptoms can be quickly relieved in the first two cycles of treatment in most patients, which results in a better nutritional status. In addition, 13 unresectable patients were then considered resectable and had an obviously longer median OS time than the others ( $P < 0.001$ , Figure 2C). Furthermore, based on the effectiveness of local treatment, a single oral or intravenous chemotherapy drug was used in combination. This combination obtained better regional benefits and systemic control in distant metastasis and reduced the dosage of chemotherapy drugs and adverse events. Thus, locally advanced GC patients could acquire higher surgical conversion possibilities and better prognoses.

In another aspect from multivariate Cox regression analysis, appropriate treatments after cGAIC were more relevant with a higher mOS, including radical resection, intravenous chemotherapy and immunotherapy after cGAIC. Although digestive obstruction symptoms of 76% of patients were relieved and life quality and nutritional status improved, relieving digestive obstruction did not become an independent predictor for long-term survival because cGAIC only made up a part of the whole comprehensive treatment. We believe that this treatment indirectly improved survival by improving the radical surgery rate. Two patients with squamous cell carcinoma were also treated with this treatment. In the following univariate survival analysis, this pathological type had a higher hazard ratio than signet ring cell carcinoma and adenocarcinoma, which demonstrated that this treatment was more suitable for advanced gastric or gastroesophageal junction cancer (Siewert type III). In addition, we found that patients with no chemotherapy history were more likely to benefit from cGAIC.

Although intra-arterial chemotherapy has been suggested to be safe and effective, there is still controversy surrounding chemotherapeutic drug selection and the speed of administration[27]. In this study, fluorouracil plus oxaliplatin was used as the preferred chemotherapy regimen for GC recommended by the NCCN, while the dosage of

Table 4 Univariate and Multivariate survival analysis for overall survival


Variables	n (%)	Univariate survival analysis			Multivariate survival analysis		
		HR	95%CI	P value	HR	95%CI	P value
Gender							
Male	20 (69)	1.53	0.49-4.85	0.466			
Female	9 (31)	1					
Intravenous chemotherapy history							
No	22 (76)	0.30	0.11-0.83	0.020			
Yes	7 (24)	1					
Gastric cancer surgery history							
No	27 (93)	0.51	0.12-2.29	0.381			
Yes	2 (7)	1					
Pathology							
Squamous cell carcinoma	2 (7)	9.24	1.62-52.69	0.012			
Signet ring cell carcinoma	8 (27)	0.66	0.18-2.44	0.535			
Adenocarcinoma	19 (66)	1					
Tumor invasion							
≤ T4a	19 (66)	0.48	0.17-1.32	0.153			
T4b	10 (34)	1					
Metastasis							
No	9 (31)	0.63	0.20-1.98	0.425			
Yes	20 (69)						
Obstructive location							
Gastroesophageal junction	6 (21)	1.21	2.24-6.10	0.816			
Pylorus	21 (72)	0.35	0.07-1.68	0.188			
Anastomosis	2 (7)	1					
Stooler's Dysphagia Score							
III	22 (76)	0.34	0.11-1.02	0.055			
IV	7 (24)	1					
Relieve digestive obstruction							
No	7 (24)	2.55	0.84-7.72	0.098			
Yes	22 (76)						
Radical resection after cGAIC							
No	16 (55)	9.56	2.11-43.44	0.003	8.48	1.27-56.51	0.027
Yes	13 (45)						
Intravenous chemotherapy after cGAIC							
No	10(34)	6.20	2.14-18.00	0.001	8.61	1.42-52.17	0.019
Yes	19(66)						
Immunotherapy after cGAIC							
No	18(62)	4.12	0.93-18.28	0.063	13.09	1.64-104-12	0.015
Yes	11(38)						

HR: Hazard ratio; CI: Confidence interval; cGAIC: Continuous gastric artery infusion chemotherapy.


**Table 5** Adverse events after constant gastric artery infusion chemotherapy

Adverse events	Grade 1, n (%)	Grade 2, n (%)
Nausea and vomiting	4 (13.8)	2 (6.9)
Abdominal pain	3 (10.3)	1 (3.4)
Gastrointestinal hemorrhage	0 (0)	0 (0)
Neutropenia	2 (6.9)	2 (6.9)
Anemia	1 (3.4)	0 (0)
Thrombocytopenia	2 (6.9)	2 (6.9)
Paresthesia	1 (3.4)	1 (4.3)
Liver enzyme increased	1 (3.4)	3 (10.3)

Common Terminology Criteria for Adverse Events Version 5.0. Data in parentheses are percentages.



**Figure 2** Overall survival time of advanced gastric cancer patients and subgroup analysis. A: The overall survival time of advanced gastric cancer patients with digestive obstruction after continuous gastric artery infusion chemotherapy (cGAIC). The mOS was 16 mo; B: Subgroup analysis between patients who got obstruction relieved and patients not; C: Subgroup analysis between patients who received radical surgery and patients not. Relief: Patients with digestive obstruction got relieved after cGAIC. Not relief: Patients with digestive obstruction didn't get relieved after cGAIC. Convert: Initially unresectable gastric cancer patients converted into resectable successfully. Unconvert: Initially unresectable gastric cancer patients failed to convert into resectable.



DOI: 10.4251/wjgo.v15.i7.1283 Copyright ©The Author(s) 2023.

**Figure 3 Comparison between pre and post continuous gastric artery infusion chemotherapy in patient with gastroesophageal junction obstruction.** A and B: gastroesophageal junction obstruction (red arrow) in abdominal contrast-enhanced computed tomography (CT) before continuous gastric artery infusion chemotherapy (cGAIC); C and D: C-arm computed tomographic angiography was used to find the tumor-feeding artery accurately in right gastroepiploic artery; E and F: Tumor in gastric fundus shrank obviously, blurred boundary became clear, and blocked digestive tract opened again in gastroesophageal junction (blue arrow), shown in abdominal contrast-enhanced CT in 2 wk after first cGAIC.

oxaliplatin was reduced by half for patients in poor general condition. A few patients with mild gastrointestinal reactions and leukopenia quickly returned to normal after symptomatic treatment.

This study was limited by the small sample size and short observation period. As a new effective method in theory, we did not set a control group at the same period, so we can only compare the effectiveness with the external control group. Moreover, this was a retrospective analysis but not prospective randomized, which may cause selection and recall biases. In addition, we did not embolize the tumor-feeding artery. In addition, the optimal cycles of cGAIC need to be explored in the future. The safety of embolization needs to be verified in randomized trials to avoid the occurrence of serious adverse effects, such as ischemia, ulcer, perforation and bleeding.

## CONCLUSION

In conclusion, this study preliminarily demonstrated the efficacy and safety of cGAIC in relieving digestive obstruction in advanced GC, which improved radical resection possibility after cGAIC and survival time. Intraoperative CACTA can help with precise definition of the perfusion area.

## ARTICLE HIGHLIGHTS

### Research background

Patients with digestive obstruction generally have advanced gastric cancer, affecting their quality of life and survival.

### Research motivation

Existing methods cannot relieve digestive obstruction very well.

### Research objectives

Continuous gastric artery infusion chemotherapy (cGAIC) was effective and safe in relieving digestive obstruction.



## Research methods

Twenty-nine patients with digestive obstruction of advanced gastric cancer treated by cGAIC were reviewed retrospectively. Interventional treatments combined with C-arm computed tomographic angiography were performed to accurately infuse oxaliplatin into the tumor-feeding artery. Radiology responses, Stooler's Dysphagia Score and toxic effects were evaluated.

## Research results

The overall response rate was 89.7% after cGAIC. The postoperative Stooler's Dysphagia Score was significantly reduced. Twenty-two (75.9%) of the 29 patients experienced relief of digestive obstruction after the first two cycles, and 13 (44.8%) initially unresectable patients were then considered radically resectable. The median overall survival time was 16 mo.

## Research conclusions

The efficacy and safety of cGAIC in relieving digestive obstruction were demonstrated, and cGAIC could improve radical resection after cGAIC and survival time. Intraoperative CACTA can help with precise definition of the perfusion area.

## Research perspectives

To improve the efficacy of chemotherapy using interventional methods.

---

## ACKNOWLEDGEMENTS

We gratefully acknowledge the assistance of all the patients and their families volunteer to participate in the clinical study.

---

## FOOTNOTES

**Author contributions:** Tang R reviewed the literature and contributed to article drafting and statistical analysis; Li B was responsible for data acquisition and revision of the manuscript; Chao M was in charge of this project and responsible for the final revision of the manuscript; Chen GF was a surgeon from Department of Gastrointestinal Surgery, and was responsible for the evaluation of surgical indications of all patients; Jin K, and Zhang GQ were interventional physicians from the Department of Radiology, and participated in the diagnosis and treatment of patients; Wu JJ, and Han SG were experienced radiologists responsible for assessment of radiology response; all authors gave final approval for the version to be submitted.

**Institutional review board statement:** The study was reviewed and approved by the Ethics Committee of The Second Affiliated Hospital of Zhejiang University School of Medicine (Approval No. I2020001737).

**Informed consent statement:** All study participants or their legal guardian gave signed informed consent.

**Conflict-of-interest statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Data sharing statement:** Dataset available from the corresponding author at [chaoming@zju.edu.cn](mailto:chaoming@zju.edu.cn). Participants gave informed consent for data sharing.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Rui Tang 0000-0002-6169-9543; Kai Jin 0000-0002-1769-2328; Guang-Qiang Zhang 0000-0002-0004-2951; Jian-Jun Wu 0000-0002-3810-1101; Shu-Gao Han 0000-0002-4842-1790; Bin Li 0000-0002-4469-752X; Ming Chao 0000-0003-0513-0683.

**S-Editor:** Yan JP

**L-Editor:** A

**P-Editor:** Yan JP

---

## REFERENCES

- 1 Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG,

- Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2016; **14**: 1286-1312 [PMID: 27697982 DOI: 10.6004/jnccn.2016.0137]
- 2 **Chen W**, Zheng R, Zeng H, Zhang S. The incidence and mortality of major cancers in China, 2012. *Chin J Cancer* 2016; **35**: 73 [PMID: 27484217 DOI: 10.1186/s40880-016-0137-8]
- 3 **Chen JH**, Wu CW, Lo SS, Li AF, Hsieh MC, Shen KH, Lui WY. Outcome of distal gastric cancer with pyloric stenosis after curative resection. *Eur J Surg Oncol* 2007; **33**: 556-560 [PMID: 17329063 DOI: 10.1016/j.ejso.2007.01.020]
- 4 **Japanese Gastric Cancer Association**. Japanese gastric cancer treatment guidelines 2018 (5th edition). *Gastric Cancer* 2021; **24**: 1-21 [PMID: 32060757 DOI: 10.1007/s10120-020-01042-y]
- 5 **Jain P**. Self-expanding metallic esophageal stents: a long way to go before a particular stent can be recommended. *World J Gastroenterol* 2011; **17**: 5327-5328 [PMID: 22219604 DOI: 10.3748/wjg.v17.i48.5327]
- 6 **Tey J**, Zheng H, Soon YY, Leong CN, Koh WY, Lim K, So JBY, Shabbir A, Tham IWK, Lu J. Palliative radiotherapy in symptomatic locally advanced gastric cancer: A phase II trial. *Cancer Med* 2019; **8**: 1447-1458 [PMID: 30790469 DOI: 10.1002/cam4.2021]
- 7 **Jiao X**, Zhou Y. Investigation of the potential role of preoperative chemotherapy in treatment for gastric cancer with outlet obstruction. *Mol Clin Oncol* 2015; **3**: 1177-1183 [PMID: 26623073 DOI: 10.3892/mco.2015.587]
- 8 **Long B**, Yu ZY, Li Q, Du HR, Wang ZJ, Zhan H, Jiao ZY. A systematic review and network meta-analysis protocol of neoadjuvant treatments for patients with gastric cancer. *Medicine (Baltimore)* 2018; **97**: e0392 [PMID: 29642200 DOI: 10.1097/MD.00000000000010392]
- 9 **Al-Batran SE**, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegeler W, Pohl M, Stoecklacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Lohr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozael W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019; **393**: 1948-1957 [PMID: 30982686 DOI: 10.1016/S0140-6736(18)32557-1]
- 10 **Zhang X**, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. *Lancet Oncol* 2021; **22**: 1081-1092 [PMID: 34252374 DOI: 10.1016/S1470-2045(21)00297-7]
- 11 **Guo H**, Ding P, Sun C, Yang P, Tian Y, Liu Y, Lowe S, Bentley R, Li Y, Zhang Z, Wang D, Zhao Q. Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial. *Front Oncol* 2022; **12**: 927781 [PMID: 36091139 DOI: 10.3389/fonc.2022.927781]
- 12 **Newman E**, Marcus SG, Potmesil M, Sewak S, Yee H, Sorich J, Hayek M, Muggia F, Hochster H. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. *J Gastrointest Surg* 2002; **6**: 212-23; discussion 223 [PMID: 11992807 DOI: 10.1016/s1091-255x(01)00054-3]
- 13 **Ouyang G**, Pan G, Xu H, Wu Y, Liu Z, Lu W, Yi B, Chen X. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. *J Clin Gastroenterol* 2020; **54**: 675-681 [PMID: 32569032 DOI: 10.1097/MCG.0000000000001384]
- 14 **Satake H**, Miki A, Kondo M, Kotake T, Okita Y, Hatachi Y, Yasui H, Imai Y, Ichikawa C, Murotani K, Hashida H, Kobayashi H, Kotaka M, Kato T, Kaihara S, Tsuji A. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI). *ESMO Open* 2017; **2**: e000130 [PMID: 28761726 DOI: 10.1136/esmoopen-2016-000130]
- 15 **Li Y**, Chen J, He Q, Ji X, Wang X, Fan C, Li G. Clinical efficacy of neoadjuvant chemotherapy regimens FLEEOX vs. XELOX in patients with initially unresectable advanced gastric cancer: a propensity score analysis. *Oncotarget* 2017; **8**: 86886-86896 [PMID: 29156843 DOI: 10.18632/oncotarget.19004]
- 16 **Zhang CW**, Zou SC, Shi D, Zhao DJ. Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer. *World J Gastroenterol* 2004; **10**: 3070-3072 [PMID: 15378797 DOI: 10.3748/wjg.v10.i20.3070]
- 17 **Zhang C**, Li G, Fan C, Xu J, Cao J, Liu S, Li N. Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer. *World J Surg Oncol* 2012; **10**: 162 [PMID: 22891660 DOI: 10.1186/1477-7819-10-162]
- 18 **Washington K**. 7th edition of the AJCC cancer staging manual: stomach. *Ann Surg Oncol* 2010; **17**: 3077-3079 [PMID: 20882416 DOI: 10.1245/s10434-010-1362-z]
- 19 **Inoue K**, Nakane Y, Kogire M, Fujitani K, Kimura Y, Imamura H, Tamura S, Okano S, Kwon AH, Kurokawa Y, Shimokawa T, Takiuchi H, Tsujinaka T, Furukawa H. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer. *Eur J Surg Oncol* 2012; **38**: 143-149 [PMID: 22154885 DOI: 10.1016/j.ejso.2011.11.009]
- 20 **Wang M**, Wu M, Wang W, Wang Q, Wang Y. Docetaxel plus S-1 versus oxaliplatin plus S-1 for first-line treatment of patients with advanced gastric cancer: a retrospective study. *Oncol Res Treat* 2014; **37**: 24-28 [PMID: 24613905 DOI: 10.1159/000358162]
- 21 **Kruk-Bachonko J**, Krupski W, Czechowski M, Kurys-Denis E, Mądro P, Sierocińska-Sawa J, Dąbrowski A, Wallner G, Skoczylas T. Perfusion CT - A novel quantitative and qualitative imaging biomarker in gastric cancer. *Eur J Radiol* 2017; **95**: 399-408 [PMID: 28987697 DOI: 10.1016/j.ejrad.2017.08.033]
- 22 **Therasse P**, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000; **92**: 205-216 [PMID: 10655437 DOI: 10.1093/jnci/92.3.205]
- 23 **Jiang L**, Ma Z, Ye X, Kang W, Yu J. Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer. *World J Surg Oncol* 2021; **19**: 44 [PMID: 33563277 DOI: 10.1186/s12957-021-02157-x]
- 24 **Tao HQ**, Zou SC. Effect of preoperative regional artery chemotherapy on proliferation and apoptosis of gastric carcinoma cells. *World J Gastroenterol* 2002; **8**: 451-454 [PMID: 12046068 DOI: 10.3748/wjg.v8.i3.451]
- 25 **Ji X**, Yang Q, Qin H, Zhou J, Liu W. Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer. *J Int Med Res* 2019; **47**: 2524-2532 [PMID: 31039658 DOI: 10.1177/0300060519845491]



- 26 **Wang J**, Shi H, Yang G, Han G, Zhao M, Duan X, Mi L, Han X, Li N, Shi J, Yin X, Yin F. Combined intra-arterial and intravenous chemotherapy for unresectable, advanced gastric cancer has an improved curative effect compared with intravenous chemotherapy only. *Oncol Lett* 2018; **15**: 5662-5670 [PMID: [29556303](#) DOI: [10.3892/ol.2018.8068](#)]
- 27 **Li M**, Zhang J, Wang D, Zhong B, Tucker S, Lu C, Cheng J, Cao C, Xu J, Pan H. A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer. *Anticancer Drugs* 2009; **20**: 941-945 [PMID: [19745719](#) DOI: [10.1097/CAD.0b013e328331af3a](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

